SCHEMBL5205838

SCHEMBL5205838

COc1ccc2[nH]c(C)c(CC(=O)Nc3ccc(C)cc3C(=O)O)c2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1C2 P52895 1/20 0.61
▸ MAPT P10636 6/20 0.52
▸ MEN1 O00255 5/20 0.51
▸ KMT2A Q03164 5/20 0.51
▸ GAA P10253 4/20 0.51
▸ ALDH1A1 P00352 4/20 0.51
▸ KDM4E B2RXH2 3/20 0.51
▸ MTNR1A P48039 2/20 0.51
▸ MTNR1B P49286 2/20 0.51
▸ HDAC1 Q13547 5/20 0.50
▸ PTPN5 P54829 1/20 0.47
▸ POLB P06746 2/20 0.46
▸ HTR1D P28221 1/20 0.46
▸ HTR6 P50406 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ NTRK1 P04629 1/20 0.46
▸ LMNA P02545 2/20 0.46
▸ ALOX12 P18054 1/20 0.46
▸ HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5214528 0.92 AKR1C2 (0.61) AKR1C2MAPTMEN1KMT2AGAA
SCHEMBL5209948 0.90 MAPT (0.62) AKR1C2MAPTMEN1KMT2AGAA
SCHEMBL5206552 0.89 AKR1C2 (0.63) AKR1C2MAPTMEN1KMT2AALDH1A1
SCHEMBL5210270 0.87 AKR1C2 (0.60) AKR1C2MAPTMEN1KMT2AGAA
SCHEMBL5274070 0.86 AKR1C2 (0.58) AKR1C2MAPTMEN1KMT2AGAA
SCHEMBL5208570 0.84 AKR1C2 (0.59) AKR1C2MAPTMEN1KMT2AGAA
SCHEMBL5208935 0.84 MEN1 (0.62) AKR1C2MAPTMEN1KMT2AALDH1A1
SCHEMBL5209238 0.84 AKR1C2 (0.59) AKR1C2MAPTMEN1KMT2AGAA
SCHEMBL5211125 0.83 AKR1C2 (0.58) AKR1C2MAPTMEN1KMT2AGAA
SCHEMBL5211075 0.82 AKR1C2 (0.56) AKR1C2MAPTMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288564-B2 Indole derivatives GLAXO GROUP LIMITED (GB) 2007-10-30 — — US claimed
US-7288564-B2 Indole derivatives GLAXO GROUP LIMITED (GB) 2007-10-30 — — US disclosed
EP-1343757-B1 INDOLE DERIVATIVES GLAXO GROUP LTD (GB) 2007-02-14 — — EP disclosed
US-20040092569-A1 Indole derivatives GLAXO GROUP LIMITED (GB) 2004-05-13 — — US disclosed
EP-1343757-A1 INDOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-09-17 — — EP disclosed
WO-2002050031-A1 INDOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2002-06-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092569-A1 Indole derivatives PTGER4, PTGER1, TRPV4 AKR1C2 1632/4885MAPT 788/4885MEN1 2074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback